ClinicalTrials.gg
CompletedNCT04869384eMOFEEUpdated Nov 4, 2024

Effect of Electronic Monitoring and Feedback on Adherence to Easyhaler Controller Medication in Patients With Asthma

A Phase 4 interventional study of Reminders and feedback to improve adherence and No reminders and feedback to improve adherence in Asthma, sponsored by Orion Corporation, Orion Pharma. Completed at 1 site in Germany. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-11-04.

Sponsored by Orion Corporation, Orion Pharma · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
158
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 21 studies in Asthma by Orion Corporation, Orion Pharma — none open to participants now, none under way, none of them phase 3. Asthma · Orion Corporation, Orion Pharma.

Enrollment
4th of 19
158 · median 72
Started
2021
with 1 other
Phase 4
2 of 21
none open now
Registered
20th of 21
by date

Among the 21 studies in Asthma by Orion Corporation, Orion Pharma, this one is the 4th largest by enrollment of the 19 interventional ones that give a count, is one of 2 that started in 2021, is one of 2 in phase 4, and was the 20th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

None of the 21 studies in Asthma by Orion Corporation, Orion Pharma is open now. The open studies under Asthma, anywhere →

Who these studies take

Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 21 studies in Asthma by Orion Corporation, Orion Pharma as a file.
02

Study summary

Effect of Electronic Monitoring and Feedback on Adherence to Easyhaler Controller Medication in Patients with Asthma

03

Conditions studied

  • Asthma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main inclusion Criteria:

  • written
  • male and female subjects with documented diagnosis of asthma
  • age 18 to 65 years
  • ACT score 19 or less at screening
  • treatment wih oral or hospital or emergency department admission due to asthma exacerbation within the past year
  • subject's able to use Easyhaler inhalers and comply with study requirements

Main exclusion Criteria:

  • recent (within 1 month) asthma exacerbation
  • concomitant major respiratory disease which may complicate the measurement of asthma control
  • >20 pack-year history of smoking
  • recent upper or lower respiratory tract infection
  • pregnant or lactating female subjects
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
158 participants (actual)

Study arms

  • Experimental
    Intervention

    Subjects will receive reminders and feedback to improve their adherence via a sensor attached to Easyhaler inhaler and mobile application

    Other: Reminders and feedback to improve adherence

  • Active comparator
    Usual care

    Subjects do not receive reminders and feedback, but receive treatment as usual.

    Other: No reminders and feedback to improve adherence

Interventions

  • OtherReminders and feedback to improve adherence

    Subjects will receive reminders and feedback to improve their adherence.

  • OtherNo reminders and feedback to improve adherence

    Subjects will not receive reminders and feedback to improve their adherence.

06

What researchers measure

Primary outcomes

  1. Mean weekly adherence to controller medication

    Adherence (percentage of doses taken of the doses prescribed) to controller medication during last six weeks of study

    Time frame: Weekly during each of the last 6 weeks of treatment

07

Study locations

1 site
  • MECS Research GmbH
    Berlin, Germany
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2021 to primary completion in Apr 2024, 34 months.

Of 66 industry-sponsored phase 4 interventional studies under Asthma, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 33. This study's 34 months is above that.

Counting every sponsor, half of 156 studies reached it within 24 months; a quarter within 11 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 27, 2021
First posted
May 3, 2021
StartActual
Jun 23, 2021
Primary completionActual
Apr 24, 2024
CompletionActual
Apr 24, 2024
Last update
Nov 4, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 4, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04869384
Responsible party
Sponsor
First posted
May 3, 2021
Start date
Jun 23, 2021
Primary completion
Apr 24, 2024
Completion
Apr 24, 2024
Last update
Nov 4, 2024

Study contacts

Orion Corporation Clinical Study Director
study director · Orion Corporation, Orion Pharma

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion